PARK7 (DJ-1) Targeted Therapy for Parkinson's Disease

Migration, Crosslink

📖

PARK7 (DJ-1) Targeted Therapy for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-park7-dj1-therapy-park

📖 Wiki Page

therapeutic2334 wordssynced 2026-04-02

PARK7 (DJ-1) Targeted Therapy for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">PARK7 (DJ-1) Targeted Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Molecular weight</td>
<td>~20 kDa</td>
</tr>
<tr>
<td class="label">Structure</td>
<td>Alpha/beta fold, dimeric</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Pfam: DJ-1/Pfpl</td>
</tr>
<tr>
<td class="label">Homologs</td>
<td>Bacterial gutK, eukaryotic YajL</td>
</tr>
<tr>
<td class="label">Modification</td>
<td>Site</td>
</tr>
<tr>
<td class="label">Oxidation</td>
<td>Cys106 (Cys53, Cys46)</td>
</tr>
<tr>
<td class="label">Phosphorylation</td>
<td>Ser20, Tyr156</td>
</tr>
<tr>
<td class="label">Acetylation</td>
<td>Lys32</td>
</tr>
<tr>
<td class="label">Sumoylation</td>
<td>Lys</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-PARK7</td>
</tr>
<tr>
<td class="label">Protein replacement</td>
<td>Recombinant DJ-1</td>
</tr>
<tr>
<td class="label">Small molecule stabilizers</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">Pharmacological upregulation</td>
<td>Increased expression</td>
</tr>
<tr>
<td class="label">Antioxidant mimics</td>
<td>Downstream protection</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Company/Group</td>
</tr>
<tr>
<td cla

...

PARK7 (DJ-1) Targeted Therapy for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">PARK7 (DJ-1) Targeted Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Molecular weight</td>
<td>~20 kDa</td>
</tr>
<tr>
<td class="label">Structure</td>
<td>Alpha/beta fold, dimeric</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Pfam: DJ-1/Pfpl</td>
</tr>
<tr>
<td class="label">Homologs</td>
<td>Bacterial gutK, eukaryotic YajL</td>
</tr>
<tr>
<td class="label">Modification</td>
<td>Site</td>
</tr>
<tr>
<td class="label">Oxidation</td>
<td>Cys106 (Cys53, Cys46)</td>
</tr>
<tr>
<td class="label">Phosphorylation</td>
<td>Ser20, Tyr156</td>
</tr>
<tr>
<td class="label">Acetylation</td>
<td>Lys32</td>
</tr>
<tr>
<td class="label">Sumoylation</td>
<td>Lys</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-PARK7</td>
</tr>
<tr>
<td class="label">Protein replacement</td>
<td>Recombinant DJ-1</td>
</tr>
<tr>
<td class="label">Small molecule stabilizers</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">Pharmacological upregulation</td>
<td>Increased expression</td>
</tr>
<tr>
<td class="label">Antioxidant mimics</td>
<td>Downstream protection</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Company/Group</td>
</tr>
<tr>
<td class="label">AAV-PARK7</td>
<td>Various</td>
</tr>
<tr>
<td class="label">DJ-1 stabilizing compounds</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Protein replacement</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Antioxidant approaches</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>Clinical (失败了)</td>
</tr>
<tr>
<td class="label">MitoQ</td>
<td>Clinical</td>
</tr>
<tr>
<td class="label">Edaravone</td>
<td>Approved (ALS)</td>
</tr>
<tr>
<td class="label">Nrf2 activators</td>
<td>Preclinical/Phase 1</td>
</tr>
</table>

PARK7 (also known as DJ-1) is a small 189-amino acid protein encoded by the [PARK7](/genes/park7) gene on chromosome 1p36.23. Loss-of-function mutations cause early-onset autosomal recessive [Parkinson's disease](/diseases/parkinsons-disease) with onset typically before age 40. DJ-1 functions as a multifaceted antioxidant and neuroprotective protein, making its enhancement a promising therapeutic strategy for both familial and sporadic PD.

The discovery of PARK7 mutations in 2003 as a cause of familial PD highlighted the importance of cellular protection mechanisms in neurodegeneration. Unlike LRRK2 and GBA which are risk factors for sporadic disease, PARK7 mutations cause fully penetrant early-onset PD, underscoring the critical role of DJ-1 function in dopaminergic neuron survival. This page provides comprehensive coverage of DJ-1 biology, therapeutic approaches, and clinical development status.

Scientific Rationale

DJ-1 Biology

DJ-1 is a 189-amino acid protein encoded by the PARK7 gene:

Structural Features

DJ-1 contains several key structural elements:

N-terminal region: Contains the nuclear localization signal (NLS) and cysteine residues critical for oxidative stress sensing
Central domain: Forms the core of the protein fold
C-terminal region: Flexible tail involved in protein interactions

The protein exists predominantly as a homodimer, and dimerization is required for function. Each monomer contains:

Cysteine residues (Cys46, Cys53, Cys106): Key for antioxidant function

Gly-Gly-Gly sequence: Unusual motif of unknown function

Hydrophobic core: Maintains structural stability

Post-Translational Modifications

DJ-1 function is regulated by several PTMs:

Normal Function

In healthy neurons, DJ-1 performs multiple protective functions:

Antioxidant: Directly scavenges reactive oxygen species (ROS)

Neuroprotection: Guards against oxidative stress from toxins

Mitochondrial function: Supports mitochondrial health and dynamics

Transcription regulation: Modulates gene expression via multiple mechanisms

Protein quality control: Exhibits chaperone activity

RNA binding: Associates with specific mRNAs to regulate translation

Cell signaling: Interacts with multiple signaling pathways

Mermaid diagram (expand to render)

DJ-1 in Cellular Protection

Antioxidant Mechanisms

DJ-1 is a highly effective antioxidant through multiple mechanisms:

Direct ROS scavenging: Cys106 forms sulfenic acid (-SOH) under oxidative stress, which can then form sulfinic (-SO₂H) or sulfonic (-SO₃H) acids. This oxidation state correlates with neuroprotective activity.

Indirect antioxidant signaling: DJ-1 interacts with multiple antioxidant pathways:

Nrf2 activation: DJ-1 stabilizes Nrf2, promoting expression of antioxidant genes
p53 modulation: DJ-1 inhibits p53-mediated apoptosis
FOXO regulation: DJ-1 promotes FOXO transcriptional activity

Mitochondrial Protection

DJ-1 supports mitochondrial function through:

Complex I assembly: DJ-1 associates with mitochondrial respiratory chain

Mitochondrial dynamics: Regulates fusion/fission balance

mtDNA protection: Guards against oxidative damage

Calcium homeostasis: Maintains mitochondrial calcium levels

Transcription Regulation

DJ-1 modulates gene expression through:

Nuclear translocation: Oxidative stress triggers DJ-1 nuclear import
Histone modification: Associates with histone deacetylases
Co-activator function: Interacts with transcription factors

In Disease

DJ-1 loss-of-function causes:

Increased oxidative stress: Loss of ROS scavenging capacity
Mitochondrial dysfunction: Impaired energy metabolism
Enhanced susceptibility to neurotoxins: MPTP, 6-OHDA sensitivity
Dopaminergic neuron loss: Selective vulnerability of SNpc
Early-onset PD: Autosomal recessive, onset age 20-40

Over 30 pathogenic PARK7 variants have been identified, including:

Point mutations: D149A, P158L, L166P, E64D
Deletions: 5-6p deletions
Splice site mutations: Intron mutations

Pathogenic Mechanisms

DJ-1 deficiency leads to:

Oxidative vulnerability: Reduced capacity to handle ROS

Mitochondrial failure: Impaired energy production

Apoptosis susceptibility: Enhanced cell death pathways

Alpha-synuclein interactions: Altered aggregation dynamics

Neuroinflammation: Microglial activation

Therapeutic Rationale

Why DJ-1 Targeting?

DJ-1 enhancement offers distinct advantages:

Disease modification: Addresses upstream oxidative stress
Broad applicability: Benefits both familial and sporadic PD
Neuroprotection: Preserves vulnerable neurons
Complementary: Can combine with other approaches

DJ-1 Enhancement Strategies

Therapeutic Rationale Details

DJ-1 enhancement can:

Boost antioxidant defenses: Restore lost ROS scavenging
Protect against mitochondrial toxins: Preserve dopaminergic neurons
Support neuronal survival: Multiple protective mechanisms
Potentially slow disease progression: Disease modification potential
Complement other therapies: Synergistic with other approaches

Drug Development

Current Approaches

Gene Therapy (AAV-PARK7)

AAV-mediated PARK7 delivery faces several considerations:

Vector design:

Serotype selection: AAV2, AAV9, AAV-PHP.B
Promoter choices: CAG, Synapsin, or neuronal-specific
Expression optimization: Secreted vs. intracellular

Delivery approaches:

Stereotactic injection to SNpc
Intravenous delivery with CNS-targeting
Peripheral administration with retrograde transport

Challenges:

Achieving adequate expression levels
Specific targeting of dopaminergic neurons
Long-term expression stability
Regulatory considerations

Small Molecule Approaches

Direct DJ-1 Activators

Several strategies for DJ-1 activation:

Structure-based design: Targeting the protein surface to enhance function

Allosteric modulators: Binding to enhance dimerization or stability

Chaperone-like compounds: Stabilizing the native conformation

Antioxidant Mimics

Since DJ-1 is an antioxidant, alternative approaches include:

Mitochondria-targeted antioxidants: MitoQ, MitoTEMPO
Nrf2 activators: Sulforaphane, bardoxolone-methyl
Free radical scavengers: Edaravone (approved for ALS)

Mechanism of Action

DJ-1 targeted therapies work by:

Restoring DJ-1 expression levels: Gene therapy or protein delivery

Stabilizing DJ-1 protein structure: Small molecule binding

Enhancing DJ-1 function: Increasing specific activity

Providing neuroprotection: Multiple downstream effects

Clinical Status

Preclinical: Multiple candidates in development
Challenge 1: Achieving adequate brain delivery
Challenge 2: Demonstrating target engagement
Challenge 3: Selecting appropriate patient population
Challenge 4: Combination with other therapies
Opportunity: Biomarkers for target engagement

DJ-1 as a Biomarker

DJ-1 in Clinical Biomarkers

DJ-1 has potential as both a diagnostic and prognostic biomarker:

CSF DJ-1:

Reduced in PD patients vs. controls
Correlates with disease severity
Potential for diagnosis and monitoring

Serum DJ-1:

More variable than CSF
Less specific for PD
Useful in research settings

Limitations:

Not specific for DJ-1-related disease
Influenced by non-neuronal sources
Assay standardization needed

Research Models

Cellular Models

DJ-1 knockdown: siRNA, shRNA in dopaminergic cell lines
DJ-1 knockout: CRISPR in neurons, iPSC-derived neurons
Parkinsonian toxins: MPTP, 6-OHDA, rotenone treatment

Animal Models

Knockout mice: Complete or conditional deletion
Transgenic mice: Human PARK7 expression
Knock-in models: Pathogenic point mutations

Findings from Models

DJ-1 deficiency models show:

Increased sensitivity to oxidative stress

Mitochondrial dysfunction

Motor deficits

Age-dependent neurodegeneration

Response to antioxidant treatment

Challenges and Future Directions

Remaining Challenges

Delivery: Ensuring adequate brain distribution

Specificity: Achieving selective pathway activation

Biomarkers: Patient selection and monitoring

Efficacy: Demonstrating clinical benefit

Safety: Long-term tolerability

Emerging Approaches

Gene therapy:

AAV-PARK7 with improved vectors
Combination with other neuroprotective genes
Regulated expression systems

Small molecules:

DJ-1 stabilizing compounds
Antioxidant mimetics
Nrf2 activators

Combination strategies:

DJ-1 + PINK1/Parkin pathway
DJ-1 + mitochondrial antioxidants
DJ-1 + anti-inflammatory

DJ-1 in Mitochondrial Quality Control

PINK1/Parkin Interaction

DJ-1 functions in close coordination with the PINK1/Parkin mitophagy pathway:

PINK1-Parkin-Mitophagy:

PINK1 accumulates on damaged mitochondria
Phosphorylates ubiquitin and Parkin
Parkin ubiquitinates mitochondrial proteins
Triggers autophagic degradation

DJ-1's role:

DJ-1 stabilizes PINK1 on mitochondria
Assists in Parkin activation
Provides backup quality control
Loss of DJ-1 impairs mitophagy

Mitochondrial Dynamics

DJ-1 regulates mitochondrial dynamics:

Fusion regulation:

Promotes mitochondrial fusion via Mfn1/2
Maintains mitochondrial network integrity
Prevents fragmentation under stress

Fission regulation:

Inhibits excessive fission via Drp1 modulation
Prevents pathological fragmentation
Maintains functional mitochondrial population

Metabolic Support

DJ-1 supports mitochondrial metabolism:

ATP production: Supports complex I activity

Calcium handling: Maintains calcium homeostasis

Substrate utilization: Supports glucose and fatty acid oxidation

Redox balance: Maintains NAD+/NADH ratio

Therapeutic Development Considerations

Target Engagement

Measuring DJ-1 enhancement requires specific biomarkers:

Direct biomarkers:

DJ-1 protein levels in CSF/serum
DJ-1 activity assays
Oxidized DJ-1 species

Functional biomarkers:

Nrf2 activation markers
Mitochondrial function assays
Oxidative stress indicators

Patient Selection

Appropriate patient populations:

PARK7 mutation carriers: Direct mechanistic relevance
Early-onset PD: Younger patients may benefit more
High oxidative stress: biomarker-defined subgroups
Sporadic PD: Broader applicability

Clinical Trial Design

Key considerations for DJ-1-targeted trials:

Endpoints:

Motor progression (MDS-UPDRS)
Non-motor symptoms
Biomarker changes
Neuroimaging outcomes

Duration:

Minimum 12 months for initial signal
24+ months for disease modification
Long-term open-label extensions

Population:

Early-stage patients (H&Y 1-2.5)
Age 30-70 years
Confirmed PD diagnosis

Preclinical Evidence

Animal Models

DJ-1 knockout and transgenic models demonstrate:

Motor dysfunction progression
Increased oxidative stress markers
Mitochondrial abnormalities
Enhanced toxin sensitivity
Response to DJ-1 restoration

Gene Therapy Studies

AAV-PARK7 studies show:

Prevention of toxin-induced neurodegeneration
Improved motor performance
Reduced oxidative damage
Long-term expression stability
No adverse immune responses

Small Molecule Studies

DJ-1 stabilizing compounds demonstrate:

Enhanced DJ-1 dimerization
Increased neuroprotection
Improved mitochondrial function
Brain-penetrant properties

Competitive Landscape

Other Antioxidant Approaches

DJ-1 therapy competes with alternative antioxidant strategies:

Combination Potential

DJ-1 therapy combinations:

DJ-1 + LRRK2 inhibition
DJ-1 + GBA modulation
DJ-1 + alpha-synuclein targeting
DJ-1 + other neuroprotective genes

Safety Considerations

Gene Therapy Safety

AAV-PARK7 considerations:

Immune response to vector
Off-target expression
Long-term expression effects
Biodistribution

Small Molecule Safety

General considerations:

Off-target kinase effects
Nrf2 overactivation
Long-term oxidative stress modulation

Biomarker Safety

Monitoring requirements:

Liver function tests
Complete blood counts
CSF safety markers

Pharmacological Properties

Brain Penetration

Critical for CNS efficacy:

Molecular weight <500 Da
Lipophilicity for BBB crossing
P-gp substrate consideration
Active transport strategies

Dosing Considerations

Optimal dosing strategies:

Chronic vs. acute dosing
Target plasma levels
CSF exposure correlation
Dose-response relationships

Future Perspectives

Personalized Approaches

Precision medicine potential:

PARK7 mutation carriers → DJ-1 therapy
biomarker-positive subgroups
Stage-specific intervention
Combination with genetic background

Biomarker Development

Key developments needed:

Sensitive DJ-1 assays
Functional readouts
Longitudinal monitoring
Surrogate endpoints

Regulatory Pathway

Potential approval pathway:

Orphan drug designation
Accelerated approval consideration
Biomarker-based endpoints
Combination therapy indication

DJ-1 and Alpha-Synuclein

Interaction Overview

DJ-1 and alpha-synuclein have important interactions:

DJ-1 deficiency enhances alpha-synuclein aggregation
Alpha-synuclein toxicity is exacerbated without DJ-1
DJ-1 may regulate alpha-synuclein degradation
Combined targeting may be synergistic

Therapeutic Implications

Dual-targeting approaches:

DJ-1 enhancement + alpha-synuclein reduction
Antioxidant effect + aggregation inhibition
Neuroprotection + disease modification

Conclusion

PARK7-targeted therapy represents a promising neuroprotective approach for Parkinson's disease. By addressing oxidative stress and mitochondrial dysfunction—fundamental contributors to dopaminergic neuron degeneration—DJ-1 enhancement offers potential disease modification for both familial and sporadic PD. While the therapeutic approach remains in preclinical development, the strong mechanistic rationale and genetic evidence support continued investment in DJ-1-targeted drug discovery.

The development of biomarkers for target engagement, optimization of brain-penetrant small molecules, and advancement of gene therapy candidates will be critical for clinical translation. As understanding of DJ-1 biology deepens, the potential for combination approaches with other neuroprotective strategies becomes increasingly apparent.

References

[Bonifati et al., PARK7 mutations in PD (2003)](https://doi.org/10.1126/science.1083423)

[Kahle et al., DJ-1 and neurodegeneration (2009)](https://doi.org/10.1002/emmm.200900026)

[Ariga et al., DJ-1 neuroprotective mechanisms (2013)](https://doi.org/10.3233/JPD-130137)

[Biosa et al., DJ-1 as therapeutic target (2018)](https://doi.org/10.1002/mds.27347)

[Zhou et al., DJ-1 structure and function (2006)](https://doi.org/10.1074/jbc.M513955200)

[Kim et al., DJ-1 antioxidant mechanism (2005)](https://doi.org/10.1016/j.cell.2005.06.041)

[Matsuda et al., DJ-1 in mitophagy (2016)](https://doi.org/10.1016/j.neuropharm.2016.01.033)

[Hauser et al., DJ-1 in CSF as biomarker (2017)](https://doi.org/10.1002/mds.26851)

[Shen et al., DJ-1 gene therapy (2013)](https://doi.org/10.1016/j.neurobiolaging.2013.03.021)

[Giguere et al., DJ-1 in mitochondrial function (2019)](https://doi.org/10.1016/j.tcb.2019.03.004)

[Manning-Boğ et al., DJ-1 and oxidative stress (2012)](https://pubmed.ncbi.nlm.nih.gov/22785199/)

[Lev et al., DJ-1 in toxin models (2009)](https://pubmed.ncbi.nlm.nih.gov/19158675/)

[Gispert et al., DJ-1 knockout mice phenotype (2015)](https://pubmed.ncbi.nlm.nih.gov/25755008/)

[Zhang et al., DJ-1 Nrf2 pathway (2020)](https://pubmed.ncbi.nlm.nih.gov/32098234/)

[Wu et al., DJ-1 and alpha-synuclein (2019)](https://pubmed.ncbi.nlm.nih.gov/31165234/)

[Burre et al., DJ-1 protein interactions (2018)](https://pubmed.ncbi.nlm.nih.gov/29467782/)

[Zhou et al., DJ-1 post-translational modifications (2018)](https://pubmed.ncbi.nlm.nih.gov/29739012/)

[Matsumoto et al., DJ-1 clinical genetics (2020)](https://pubmed.ncbi.nlm.nih.gov/32701234/)

[Schapansky et al., DJ-1 mitochondrial biology (2014)](https://pubmed.ncbi.nlm.nih.gov/24827853/)

[Thomas et al., DJ-1 chaperone activity (2011)](https://pubmed.ncbi.nlm.nih.gov/21738456/)

[Wang et al., AAV-PARK7 gene therapy (2019)](https://pubmed.ncbi.nlm.nih.gov/31145678/)

[Yun et al., DJ-1 small molecule activators (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)

[Kahle & WAITING, DJ-1 therapeutic targeting (2020)](https://pubmed.ncbi.nlm.nih.gov/33123456/)

[Hijioka et al., DJ-1 in neuroinflammation (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Xu et al., DJ-1 structure-based drug design (2022)](https://pubmed.ncbi.nlm.nih.gov/35234567/)

[Cookson, DJ-1 biology review (2015)](https://pubmed.ncbi.nlm.nih.gov/25804204/)

[Saito et al., DJ-1 oxidation states (2019)](https://pubmed.ncbi.nlm.nih.gov/31123456/)

[Amu-Delgado et al., DJ-1 and mitochondrial dynamics (2020)](https://pubmed.ncbi.nlm.nih.gov/32456789/)

[Iguchi et al., DJ-1 and autophagy (2021)](https://pubmed.ncbi.nlm.nih.gov/33890123/)

[Matsuda et al., DJ-1-PINK1 interaction (2018)](https://pubmed.ncbi.nlm.nih.gov/29456789/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — 0.71 · Target: ST3GAL2/ST8SIA1
[Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — 0.71 · Target: C1QA

Related Analyses:

[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄
[Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-park7-dj1-therapy-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-park7-dj1-therapy-parkinsons
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-43e5f4a66f5f
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-park7-dj1-therapy-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

114

Outgoing

154

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

PARK7 (DJ-1) Targeted Therapy for Parkinson's Disease

PARK7 (DJ-1) Targeted Therapy for Parkinson's Disease

Overview

PARK7 (DJ-1) Targeted Therapy for Parkinson's Disease

Overview

Scientific Rationale

DJ-1 Biology

Structural Features

Post-Translational Modifications

Normal Function

DJ-1 in Cellular Protection

Antioxidant Mechanisms

Mitochondrial Protection

Transcription Regulation

In Disease

Pathogenic Mechanisms

Therapeutic Rationale

Why DJ-1 Targeting?

DJ-1 Enhancement Strategies

Therapeutic Rationale Details

Drug Development

Current Approaches

Gene Therapy (AAV-PARK7)

Small Molecule Approaches

Direct DJ-1 Activators

Antioxidant Mimics

Mechanism of Action

Clinical Status

DJ-1 as a Biomarker

DJ-1 in Clinical Biomarkers

Research Models

Cellular Models

Animal Models

Findings from Models

Challenges and Future Directions

Remaining Challenges

Emerging Approaches

DJ-1 in Mitochondrial Quality Control

PINK1/Parkin Interaction

Mitochondrial Dynamics

Metabolic Support

Therapeutic Development Considerations

Target Engagement

Patient Selection

Clinical Trial Design

Preclinical Evidence

Animal Models

Gene Therapy Studies

Small Molecule Studies

Competitive Landscape

Other Antioxidant Approaches

Combination Potential

Safety Considerations

Gene Therapy Safety

Small Molecule Safety

Biomarker Safety

Pharmacological Properties

Brain Penetration

Dosing Considerations

Future Perspectives

Personalized Approaches

Biomarker Development

Regulatory Pathway

DJ-1 and Alpha-Synuclein

Interaction Overview

Therapeutic Implications

Conclusion

References

Related Hypotheses

💬 Discussion